Humira (also know by its generic name adalimumab) is a TNF-alpha inhibitor biologic approved by the FDA in October 2005 for use in adult patients to treat active psoriatic arthritis and in January 2008 to treat moderate-to-severe psoriasis. It is also approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.
For adult patients with psoriatic arthritis, Humira is administered every other week. For adult patients with psoriasis, Humira is administered at week 0 and then every other week starting one week after initial dose. Humira is administered by injection under the skin.
To learn more, please visit the Humira website.
Biosimilars for Humira
A biosimilar is a medication that is highly similar to an existing FDA-approved biologic medicine (aka reference product). Biosimilars have the same strength, dosage, potential benefits and side effects as the reference product and are administered the same way. Biosimilars still must be FDA-approved.